Acid Control Cannot Be Improved with a Modified-Release Formulation of a Proton Pump Inhibitor Compared with Twice-Daily Dosing of the Conventional Formulation
Kerstin Röhss(AstraZeneca (Sweden)), Péter Nagy(AstraZeneca (Sweden)), Clive H. Wilder‐Smith, Sara Bokelund-Singh(Stanford University), Mohamed Sagar(AstraZeneca (Sweden))
Cited by 5
Related Papers
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93
Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects
|Scandinavian Journal of Gastroenterology|1993|58